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Abstract
Toxoplasma gondii is an obligate intracellular parasite that enters cells by a process of active penetration. Host cell
penetration and parasite motility are driven by a myosin motor complex consisting of four known proteins: TgMyoA, an
unconventional Class XIV myosin; TgMLC1, a myosin light chain; and two membrane-associated proteins, TgGAP45 and
TgGAP50. Little is known about how the activity of the myosin motor complex is regulated. Here, we show that treatment of
parasites with a recently identified small-molecule inhibitor of invasion and motility results in a rapid and irreversible change
in the electrophoretic mobility of TgMLC1. While the precise nature of the TgMLC1 modification has not yet been
established, it was mapped to the peptide Val46-Arg59. To determine if the TgMLC1 modification is responsible for the
motility defect observed in parasites after compound treatment, the activity of myosin motor complexes from control and
compound-treated parasites was compared in an in vitro motility assay. TgMyoA motor complexes containing the modified
TgMLC1 showed significantly decreased motor activity compared to control complexes. This change in motor activity likely
accounts for the motility defects seen in the parasites after compound treatment and provides the first evidence, in any
species, that the mechanical activity of Class XIV myosins can be modulated by posttranslational modifications to their
associated light chains.
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Introduction
Toxoplasma gondii is a protozoan parasite of the Phylum
Apicomplexa. This phylum contains over 5,000 species, many of
which are of significant medical or veterinary importance,
including Plasmodium spp., the causative agents of malaria,
Cryptosporidium spp., the causative agents of the diarrheal disease
cryptosporidiosis, and Eimeria spp., which cause losses in the US
poultry industry exceeding $600 million annually.
Like most apicomplexans, T. gondii is an obligate intracellular
parasite. Host cell invasion is a parasite-driven, multistep process
that is necessary for parasite survival (reviewed in [1]). Prior to
invasion, parasites glide along the surface of the host cell to be
invaded, extending and retracting a tubulin-based cytoskeletal
structure, the conoid, at their extreme apical tip [2]. Invasion is
initiated by proteins released onto the parasite surface from apical
secretory organelles known as the micronemes; these proteins
mediate intimate and irreversible attachment to the host cell [3,4].
At least one microneme protein also interacts with proteins
secreted by a second set of apical organelles, the rhoptries, to form
a ring-shaped zone of tight contact between the host cell plasma
membrane (PM) and the PM of the internalizing parasite [5,6]. As
the parasite penetrates through this junction and into the host cell,
it becomes enveloped by a parasitophorous vacuole membrane
(PVM) that is derived primarily from the host cell PM [7]. In the
final step of invasion, the PVM pinches off from the host cell PM
to surround the fully internalized parasite.
Both gliding motility and host cell penetration are driven by the
same unconventional Class XIV myosin motor protein, TgMyoA
[8]. TgMyoA is a 93kDa protein consisting of a head domain,
which contains only 23–34% identity to other myosin heavy
chains, and a short neck/tail domain [9]. Although TgMyoA lacks
a number of generally well conserved sequence features, such as a
pair of cysteine residues in the converter domain and a glycine
residue that acts as the ‘‘pivot-point’’ for the lever arm in most
other myosin heavy chains [10,11], it has a step size of 5.3nm and
moves towards the plus-end of actin filaments at approximately
5 mm/s, a velocity comparable to skeletal muscle myosin [10].
The short neck/tail domain of TgMyoA binds a single,
calmodulin-like myosin light chain, TgMLC1 [10]. These two
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proteins associate with two additional proteins, TgGAP45 and
TgGAP50, to form the myosin motor complex ([12,13]; see
Fig. 1A). TgGAP45 contains predicted palmitoylation and
myristoylation sites and functions in motor complex assembly
[14,15], while TgGAP50 is a transmembrane protein that is
thought to anchor the motor complex into the inner membrane
complex (IMC) (Fig. 1A; [13,14]). The motor complex is firmly
immobilized in the IMC within cholesterol-enriched microdo-
mains [16]. Short actin filaments located between the parasite PM
and the IMC are connected to ligands on the host cell surface
through a number of bridging proteins, including TgMIC2 and
aldolase ([17]; Fig. 1A); these proteins, together with the myosin
motor complex, are collectively referred to as the glideosome
[12,13]. During invasion, when TgMyoA anchored into the IMC
undergoes its power stroke, the parasite is driven through the ring-
shaped junction and into the host cell.
The components of the myosin motor complex are highly
conserved across apicomplexan parasites [13,18], and myosin-based
motility is essential not only for invasion but also for penetrating
biological barriers and disseminating through tissues during infection
[8,18,19]. While the components of the motor complex have been
well characterized, nothing is currently known about how the activity
of the complex is regulated to generate the different speeds and types
of motility that the parasite is capable of [20]. Myosin regulation in
other systems can occur through heavy chain phosphorylation, which
can alter the actin-activated ATPase activity of the myosin, its
localization in the cell or its assembly with other myosin subunits
(reviewed in [21,22]). Myosin light chains also play a major role in
regulating the ATPase activity and stability of myosin motor proteins
[23]. The effect of a particular light chain on myosin function is
regulated by calcium binding to the light chain and/or phosphor-
ylation of the light chain by myosin light chain kinases, whose
activities are themselves regulated by intracellular calcium levels and
a variety of other signaling pathways [24]. The myosin light chain of
P. falciparum (named MTIP, for myosinA tail domain-interacting
protein) was recently shown to be phosphorylated [25], but whether
or how the myosin light chains of apicomplexan parasites contribute
to the regulation of Class XIV myosin motor function is unknown.
In a recent high-throughput screen, we identified 24 novel
small-molecule inhibitors and six enhancers of T. gondii invasion
[26]. Surprisingly, 21 out of the 24 invasion inhibitors inhibited
parasite motility and all six enhancers of invasion enhanced
parasite motility. This led us to hypothesize that some of these
small molecules exert their effects by altering the composition or
function of the T. gondii myosin motor complex. We show here that
treatment of parasites with one of the motility inhibitors results in a
posttranslational modification to TgMLC1. Furthermore, we show
that motor complexes containing the altered form of TgMLC1
have reduced mechanical activity in an in vitro motility assay. This
change in TgMyoA motor activity likely accounts for the motility
defects seen in the parasite after compound treatment and
provides the first evidence, in any apicomplexan parasite, for the
modulation of Class XIV myosin activity by myosin light chain(s).
Results
A small-molecule inhibitor of T. gondii invasion and
motility alters the electrophoretic mobility of TgMLC1
To test whether any of the inhibitors or enhancers of parasite
motility identified in our screen affect the composition of the
myosin motor complex, 35S-labeled extracellular parasites were
treated with each of the small molecules and the proteins of the
motor complex were isolated by co-immunoprecipitation with an
anti-TgGAP45 antibody, resolved by SDS-PAGE and visualized
by autoradiography. In all cases, the four major components of the
motor complex (TgMyoA, TgGAP50, TgGAP45 and TgMLC1)
were recovered (Fig. 1B). While 26 of the 27 compounds tested
had no apparent effect on motor complex composition, treatment
with one of the motility inhibitors (referred to previously as
Inhibitor 24 [26]), resulted in the association of a prominent new
30kDa protein with the motor complex (Fig. 1B, red arrow). We
have named this motility inhibitor tachypleginA (‘‘tachy’’ for
tachyzoite, ‘‘plegin’’ from the Greek-derived suffix ‘‘plegia’’, for
paralysis).
The motor complex-associated proteins were then resolved by
2D gel electrophoresis. TgGAP45, which is multiply phosphory-
lated [15], resolves as a prominent charge train (Fig. 1C, upper
panels, black arrow). TgMLC1 from DMSO-treated parasites runs
as two distinct spots (Fig. 1C, blue arrow), the more minor and
acidic of which is phosphorylated (ATH, BAB and GEW,
unpublished data). After treatment with tachypleginA, a new
35S-labeled spot is apparent immediately under the TgMLC1 spots
(Fig. 1C, upper panels, red arrow). Western blotting with an
antibody against TgMLC1 identified this new motor complex-
associated protein as a modified form of TgMLC1 (Fig. 1C, lower
panels), a result subsequently confirmed by mass spectrometry (see
below).
The TgMLC1 modification occurs within five minutes of
compound treatment in both extracellular (Fig. 2A) and
intracellular (data not shown) parasites. The modification does
not reverse to any significant extent, even two to four hours after
compound washout (Fig. 2B and data not shown). TachypleginA is
only able to induce the mobility shift when added to intact
parasites, not to parasite lysates or isolated motor complexes
(Fig. 2C). Strikingly, only ,50% of the TgMLC1 is modified in
response to tachypleginA (Figs. 1B & C, 2A–C), even after multiple
treatments and extended treatment times.
A collection of analogs of tachypleginA was generated using
parallel synthesis techniques, and each analog was tested for its
effect on invasion, motility and the TgMLC1 electrophoretic
mobility shift. While the majority of the analogs tested did not
score as inhibitors in the invasion assay (data not shown), we
identified two analogs (tachypleginA-2 and tachypleginA-3; Fig.
S1 and Text S1) that inhibited parasite invasion and motility and
Author Summary
Toxoplasma gondii and related parasites within the Phylum
Apicomplexa are collectively responsible for a great deal of
human disease and death worldwide. The ability of
apicomplexan parasites to invade cells of their hosts,
disseminate through tissues and cause disease depends
critically on parasite motility. Motility is driven by a
complex of proteins that is well conserved within the
phylum; however, very little is known about how the
unconventional myosin motor protein at the heart of this
motility machinery is regulated. T. gondii serves as a
powerful model system for studying apicomplexan motile
mechanisms. We show here that a recently identified
pharmacological inhibitor of T. gondii motility induces a
posttranslational modification of TgMLC1, a protein that
binds to the myosin motor protein, TgMyoA. The
compound-induced modification of TgMLC1 is associated
with a decrease in TgMyoA mechanical activity. These data
provide the first glimpse into how TgMyoA is regulated
and how a change in the activity of the T. gondii myosin
motor complex can affect the motility and infectivity of
this important human pathogen.
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reproducibly induced the TgMLC1 mobility shift. It was difficult
to establish structure-activity relationships among these analogs
due to the semi-quantitative nature of the in vivo assays [27] and
problems with compound stability and solubility. However, we did
not identify any analogs that induced the modification of
TgMLC1 without also inhibiting motility and invasion, consistent
with the hypothesis that the observed block in these processes
results from the modification of TgMLC1.
Mapping the site of modification
An epitope-tagged copy of TgMLC1 (Myc-TgMLC1) was
expressed in the parasites and shown to be modifiable by
tachypleginA treatment (Fig. S2). As a first step towards identifying
the site of modification, Myc-TgMLC1 truncation mutants were
generated by deletion of 79 amino acids from the N-terminus or
20 amino acids from the C-terminus (Fig. 3A). Parasites stably
expressing these truncations could not be generated, and
insufficient protein was isolated from transiently expressing
parasites for analysis of the electrophoretic mobility of the
truncated proteins in response to tachypleginA. Immunofluores-
cence analysis of individual, transiently expressing parasites
showed that while both full length TgMLC1 and Myc-
TgMLC11–193 localize to the parasite periphery, Myc-
TgMLC180–213 is distributed throughout the cytosol (Fig. S3),
suggesting that amino acids 1–79 of TgMLC1 are necessary for
proper localization.
Based on these preliminary truncation data, different N-terminal
fragments of TgMLC1 were fused to yellow fluorescent protein
(YFP) and the localization and ability of the fusion proteins to
undergo an electrophoretic mobility shift in response to tachyple-
ginA treatment were determined. A fusion protein containing
amino acids 1–79 of TgMLC1 (TgMLC11–79YFP) was found to
Figure 1. Treatment of parasites with tachypleginA induces a shift in the electrophoretic mobility of TgMLC1. (A) Current model for
how the T. gondii myosin motor complex drives parasite motility. TgMyoA, TgMLC1 and TgGAP45 are anchored to the IMC via transmembrane
protein TgGAP50. Short actin filaments located between the parasite plasma membrane and the IMC are connected to ligands on the host cell
surface through bridging proteins TgMIC2 and aldolase. See text for further details. Adapted from [49]. (B) 35S-labeled extracellular parasites were
treated for 15 minutes in medium containing: (a) DMSO; (b) 100 mM Inhibitor 22 (ref [26]); (c) 100 mM tachypleginA (structure shown in inset); or (d)
100 mM Enhancer 5 (ref [26]). Myosin motor complexes were isolated from the treated parasites by anti-TgGAP45 immunoprecipitation, and the
immunoprecipitated proteins were resolved and visualized by SDS-PAGE / autoradiography. Treatment with tachypleginA results in an extra 30kDa
protein associating with the myosin motor complex (red arrow). Numbers on the left indicate molecular mass in kDa. Asterisk indicates a degradation
product of TgGAP45 [14]. (C) Myosin motor complexes were isolated from DMSO- and tachypleginA-treated, 35S-labeled extracellular parasites by
anti-TgGAP45 immunoprecipitation. Proteins were resolved by 2D gel electrophoresis and visualized by autoradiography (upper panel) followed by
western blotting with anti-TgMLC1 (lower panel). The 30kDa protein that appears after compound treatment is recognized by the anti-TgMLC1
antibody (red arrow), indicating that a modified form of TgMLC1 associates with the myosin motor complex after tachypleginA treatment.
Unmodified TgMLC1 is indicated with a blue arrow and TgGAP45 is indicated with a black arrow. Although the phosphorylated form of TgMLC1 was
below the limit of detection by western blotting after tachypleginA treatment in this particular experiment, this was not usually the case (e.g., see Fig.
S2). Numbers on the top indicate the pH gradient used for isoelectric focusing, and numbers on the right indicate molecular mass in kDa.
doi:10.1371/journal.ppat.1000720.g001
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largely colocalize with the IMCmarker IMC1 (Fig. 3C), confirming
that the N-terminal 79 amino acids are sufficient for TgMLC1
localization to the parasite periphery. Importantly, TgMLC1
1–79YFP also undergoes an electrophoretic mobility shift in response
to tachypleginA (Fig. 3B), suggesting that the site(s) of modification
lie(s) within these first 79 amino acids. Further truncations within
these first 79 amino acids were uninformative, as TgMLC140–79YFP
and TgMLC160–79YFP localized to the cytosol, and neither
underwent an electrophoretic mobility shift in response to
tachypleginA treatment (data not shown).
Figure 2. The effect of tachypleginA on TgMLC1 is rapid, irreversible and only occurs in intact parasites. (A) Extracellular parasites were
treated with 100 mM tachypleginA or an equivalent amount of DMSO for times ranging from 5 to 120 minutes. Parasite proteins were resolved by
SDS-PAGE and TgMLC1 was visualized by anti-TgMLC1 western blot. The unmodified and modified forms of TgMLC1 are indicated with blue and red
arrows, respectively. (B) Intracellular parasites were treated with 100 mM tachypleginA or an equivalent amount of DMSO for 15 minutes. The
compound was removed and parasites were incubated at 37uC in compound-free media for the times indicated. Parasite proteins were resolved by
SDS-PAGE and visualized by anti-TgMLC1 western blot. The unmodified and modified forms of TgMLC1 are indicated with blue and red arrows,
respectively. (C) 35S-labeled extracellular parasites were treated with 100 mM tachypleginA or an equivalent amount of DMSO for 20 minutes at 25uC
and motor complexes were isolated by anti-TgGAP45 immunoprecipitation (left panel). Alternatively, motor complexes were isolated from 35S-
labeled extracellular parasites and treated with DMSO or 100 mM tachypleginA for 20 minutes at 25uC (right panel). Proteins were resolved by SDS-
PAGE and visualized by autoradiography. The unmodified and modified forms of TgMLC1 are indicated with blue and red arrows, respectively.
Numbers on the left indicate molecular mass in kDa.
doi:10.1371/journal.ppat.1000720.g002
Figure 3. Amino acids 1–79 of TgMLC1 are sufficient for the tachypleginA-induced mobility shift. (A) Schematic of the TgMLC1
truncation mutants generated. (B) Parasites transiently expressing TgMLC11–79YFP were treated with 100 mM tachypleginA or an equivalent amount
of DMSO. Proteins were resolved by SDS-PAGE and visualized by anti-GFP western blot. The unmodified and modified forms of TgMLC11–79YFP are
indicated with blue and red arrows, respectively. Asterisk (*) indicates a protein that is non-specifically recognized by the anti-GFP antibody. (C) Dual
label immunofluorescence of intracellular parasites expressing TgMLC11–79YFP, using antibodies against TgIMC1 and GFP. TgMLC11–79YFP largely
colocalizes with TgIMC1, indicating that the first 79 amino acids of TgMLC1 are sufficient for peripheral localization.
doi:10.1371/journal.ppat.1000720.g003
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Next, we used a quantitative mass spectrometry approach (Stable
Isotope Labeling by Amino Acids in Culture, or SILAC [28]) to
map the site of modification by searching for predicted tryptic
peptides within the first 79 amino acids of both the upper and the
lower, compound-induced forms of TgMLC1. Any peptide detected
at its expected mass in one of the TgMLC1 forms but not the other
could potentially contain the site of modification. Parasites were
cultured for four days in either ‘‘heavy’’ medium (i.e., medium
containing 13C6-,
15N4-arginine and
13C6-,
15N2 -lysine) or ‘‘light’’
medium (containing only natural amino acids). A four-day culture
labels parasite proteins in the heavy sample to near completion, but
still leaves a small portion of the proteins unlabeled, which was
important for quantitation (see below). The parasites cultured in
heavy media were treated with tachypleginA and the parasites
cultured in light media with an equivalent amount of DMSO. The
myosin motor complexes from each population were then isolated
and run together on the same 2D gel. The upper spot on such a 2D
gel should contain a mixture of both heavy and light TgMLC1 while
the lower spot should contain primarily heavy TgMLC1 (and
smaller amounts of light TgMLC1, since the labeling was not driven
to completion). The upper and lower spots were excised from the
gel, digested with trypsin and subjected to liquid chromatography-
tandem mass spectrometry (LC-MS/MS). Since heavy and light
peptides of the same sequence have identical chromatographic
profiles but different masses, the relative abundance of each peptide
in its heavy and light forms can be readily determined. Owing to the
natural abundance of 13C, each peptide is observed as a cluster of
peaks with the light cluster spaced apart from the heavy cluster,
consistent with the mass and number of heavy arginine and lysine
residues found in each peptide.
Multiple TgMLC1 peptides were identified from each spot. The
five most readily identified peptides in the upper spot revealed
similar light to heavy ratios, with the light peptide averaging 1.25
times more than the heavy peptide (Fig. 4B). When the relative
abundances of these same peptides were examined in the lower
spot, four of the five showed a consistent but very different ratio
from the peptides in the upper spot with an average light:heavy
ratio of 0.16 (Fig. 4A,B). The fifth peptide (V46GEYDGA-
CESPSCR59), however, showed the same ratio as that observed
in the upper spot. Furthermore, uncharacteristic of the other four
peptides, this fifth peptide was chosen by the instrument for
fragmentation six times fewer in the lower spot compared to the
upper spot, suggesting it was more abundant in the upper spot.
This suggestion was further supported when the relative
abundances of the peptide in the upper and lower spots were
compared to the relative abundance of a polydimethylcyclosilox-
ane background ion (Si(CH3)2O)6
+) that is commonly used as an
internal calibrant for mass spectrometry [29]. Using this
background ion as a reference, we estimated that the peptide
V46GEYDGACESPSCR59 was approximately 225-fold more
abundant in the upper form than in the lower form (Fig. S5).
Together, these data provide strong evidence that the trace
amount of this peptide detected in the lower form was in fact a
contaminant from the upper form. Thus, while the unmodified
form of the peptide V46GEYDGACESPSCR59 can be readily
detected in the upper TgMLC1 spot, it is effectively undetectable
in the lower compound-induced spot at its predicted (unmodified)
mass and therefore likely contains the site of compound-induced
modification. These data also suggest that compound treatment
induces the modification of this peptide, rather than removal of a
modification already present on the upper form of TgMLC1.
In an attempt to identify the precise site of modification, we
conducted LC-MS/MS analysis on the lower, compound-induced
spot of TgMLC1. Differential Sequest searches were performed
for potential phosphorylation of the peptide V46GEYDGA-
CESPSCR59 on serine, or tyrosine, as well as acetylation or
mono-, di-, and tri-methylation of arginine. Only the unmodified
peptide V46GEYDGACESPSCR59 (alkylated during the reaction
with iodoacetamide prior to resolution by 2D gel electrophoresis)
was identified, which, given the SILAC data described above, was
presumably due to trace contamination from the upper spot.
Given the many different posttranslational modifications that can
occur on cysteine [30], the data were also subjected to a series of
Sequest searches that permitted dynamic modification of Cys53
and/or Cys58 with mass values from 1 to 353 (the mass of
tachypleginA). Again, only trace contamination of unmodified
peptide was detected. Further analytical work will be required to
determine the precise site and nature of the modification, but these
data suggest either an uncommon posttranslational modification
or one that renders the peptide difficult to analyze by LC-MS/MS.
The effect of tachypleginA on myosin motor complex
function
To determine if the TgMLC1 modification affects TgMyoA
activity, parasites stably expressing FLAG-tagged TgMLC1
(FLAG-TgMLC1-WT) were generated. Highly enriched myosin
motor complexes could then be isolated from DMSO- and
tachypleginA-treated parasites by anti-FLAG affinity chromatog-
raphy (Fig. 5A). The concentration of TgMyoA in each
preparation was determined by comparing the fluorescence
intensity of the TgMyoA band to that of protein standards in
SYPRO Ruby-stained gels (Fig. S6).
The motion-generating capacity of the myosin motor complex
was measured in an in vitro motility assay, in which isolated motor
complexes were adsorbed to the surface of a nitrocellulose-coated
glass coverslip and the velocity with which these motor complexes
moved fluorescently labeled chicken skeletal muscle actin filaments
was determined (Videos S1 & S2; see also refs. [10,31,32]). When
adsorbed at low densities to the coverslip (,10 mg/ml TgMyoA),
complexes from tachypleginA-treated parasites were found to
displace actin filaments with a significantly lower velocity than
those from untreated control parasites (Fig. 5B). As the motor
density increased, the difference in velocities became progressively
smaller, and by 15 mg/ml TgMyoA the velocities of actin filament
displacement by control and tachypleginA-treated motor com-
plexes were statistically indistinguishable (Fig. 5B).
Maximal actin filament velocity (Vmax) in the motility assay is
achieved when at least one myosin head is strongly bound to the
actin filament and generating motion at every point in time [33].
The fraction of myosin’s catalytic cycle that the motor is strongly
bound to actin is defined as its duty ratio [34]. Therefore, myosins
having low duty ratios (#5%) require higher densities of myosin
on the motility surface to achieve continuous actin filament
movement at Vmax. The observation that, at low densities,
TgMyoA from tachypleginA-treated parasites generates lower
filament velocities than the same concentration of TgMyoA from
control parasites suggests that the population of TgMyoA in the
tachypleginA-treated samples has a lower duty ratio than TgMyoA
from the DMSO-treated samples, thus requiring more TgMyoA to
achieve Vmax.
The TgMyoA duty ratio was determined by calculating the
number of myosin molecules on the motility surface that are
available to interact with a given actin filament and plotting this
number against the measured displacement velocity associated with
that filament (see Materials and Methods; [33]). The data were fit to
the equation: V= (a6Vmax)6[12(12f)
n], where f is the duty ratio,
n is the number of myosin heads, and a is an efficiency factor for
coupling myosin-generated motion to actin filament movement at
T. gondii MLC1 and Motility
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low myosin densities [33,35]. Based on these fits (Fig. 5C), TgMyoA
is characterized by an extremely low duty ratio of 0.7760.07% (best
fit 6 standard error). Treatment with tachypleginA decreases the
duty ratio of the population by more than 60%, to 0.2760.02%.
Discussion
TachypleginA is a recently identified inhibitor of T. gondii
motility and invasion [26]. We show here that treatment of
parasites with tachypleginA results in a modification to TgMLC1
that alters its electrophoretic mobility. Early attempts to identify
the nature of the modification ruled out changes in phosphory-
lation state, N- or C-terminal proteolysis and differential splicing
(data not shown). Truncation analysis showed that the residue(s)
responsible for the mobility shift lie(s) within the first 79 residues of
the protein. Subsequent quantitative proteomic analysis identified
V46GEYDGACESPSCR59 as the likely modified peptide. No
common posttranslational modifications on specific residues within
this peptide could be identified. We are continuing to pursue the
nature of the modification but anticipate that it may either be a
novel type of posttranslational modification, or that the modified
peptide is selectively lost during sample preparation or does not
ionize or fragment well for mass spectrometry analysis.
It is difficult to predict how a posttranslational modification
within the peptide V46GEYDGACESPSCR59 of TgMLC1 could
cause a change in TgMyoA motor activity. Immunoprecipitation
experiments showed that the four main components of the
glideosome remain associated after tachypleginA treatment
(Fig. 1A and data not shown), indicating that drug treatment has
no appreciable effect on motor complex stability. Furthermore,
Figure 4. TachypleginA promotes the apparent posttranslational modification of TgMLC1 peptide V46GEYDGACESPSCR59. TgMLC1
from tachypleginA- and DMSO-treated parasites was isolated by immunoaffinity chromatography and 2D gel electrophoresis, and subject to LC-MS/
MS (see text for details). (A) The averaged light and heavy isotopic envelopes for one peptide (A190AEYFTSDQIDYR202) from the upper TgMLC1 spot
(left panel) and lower, tachypleginA-induced spot (right panel). SILAC ratios were generated by comparing the relative abundances of the
monoisotopic light and heavy peaks (filled and open stars, respectively). The dashed lines indicate the average relative abundances of the light vs.
heavy monoisotopic peaks of the peptides listed in Fig. 4B (average abundance of heavy peaks set to 100; error bars indicate the standard deviation
from the mean). (B) The SILAC ratios (light:heavy) for the five most readily identifiable peptides in the upper and lower spots. The average SILAC
light:heavy ratio for the upper spot (1.25) was calculated using the SILAC ratios of all five listed peptides, whereas the average for the lower spot
(0.16*) was calculated omitting the data for peptide V46GEYDGACESPSCR59 as its SILAC ratio (1.16, boxed) suggested it was a contaminant from the
upper spot. M* indicates an oxidized methionine residue. C# indicates a carbamidomethyl cysteine residue generated by alkylation with
iodoacetamide prior to running the 2D gels. See Fig. S4 for the low energy CID MS/MS spectrum of V46GEYDGACESPSCR59 and Fig. S5 for a semi-
quantitative measurement of the relative amount of this peptide present in the upper and lower spots.
doi:10.1371/journal.ppat.1000720.g004
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actin cosedimentation assays performed in the absence of ATP,
i.e., conditions under which myosin binds strongly to actin, show
that all of the detectable TgMLC1 in the parasite pellets with actin
after treatment with either DMSO or tachypleginA, indicating
that the binding of TgMLC1 to TgMyoA is not disrupted by
compound treatment (data not shown). TgMLC1 and its homologs
in other apicomplexan parasites contain a 70–82 amino acid N-
terminal extension (70 aa in TgMLC1) that is not found in most
other calmodulin-like myosin light chains. While the crystal
structure of Plasmodium yoelii MyoAtail bound to P. falciparum myosin
light chain (PfMTIP) lacking the majority of its N-terminal
extension (amino acids 1–62) has been solved [36], the structures
of full length PfMTIP and TgMLC1 have not. It is therefore not
known how the N-terminal extensions of these light chains are
oriented in relation to MyoA. Essential light chain from fast
skeletal muscle (ELC1) contains a 40 amino acid lysine-rich N-
terminal extension compared to ELC3, and this positively charged
N-terminal extension interacts with the negatively charged C-
terminus of actin [37]. TgMLC1 contains three lysine residues
near its N-terminus, so it is possible that TgMLC1 modulates
myosin motor complex activity through a similar direct interaction
with actin. Experiments are currently underway to test this
hypothesis; if correct, the tachypleginA-induced modification
could disrupt this interaction.
Figure 5. TachypleginA treatment causes a decrease in the motor activity of the TgMyoA motor complex. (A) Affinity-purified myosin
motor complexes from DMSO- and tachypleginA-treated parasites, resolved by SDS-PAGE and visualized by silver stain. The unmodified and modified
forms of TgMLC1 are indicated with blue and red arrowheads, respectively. Numbers on the left indicate molecular mass in kDa. (B) Mean actin
filament displacement velocities at different TgMyoA concentrations. Red symbols indicate motor complexes isolated from tachypleginA-treated
parasites; blue symbols indicate motor complexes isolated from DMSO-treated parasites. Squares and circles indicate data from two independent
experiments, error bars denote standard error of the mean, and green arrowheads indicate samples shown in Supplemental Videos S1 and S2. Each
data point from the DMSO-treated samples was compared to the corresponding data point from the tachypleginA-treated sample that was most
similar in TgMyoA concentration, using an independent two-tailed t-test. At all low (,10 mg/ml) TgMyoA concentrations, motor complexes isolated
from tachypleginA-treated parasites displaced actin filaments at a significantly slower velocity than motor complexes isolated from DMSO-treated
parasites (p,0.001). In contrast, at higher TgMyoA concentrations (.15 mg/ml), no statistically significant differences in displacement velocity were
observed. The data were fit by nonlinear regression to a simple hyperbola. (C) Actin filament velocity (V/Vmax) was plotted as a function of the
number of myosin heads capable of interacting with the actin filament. The calculated duty ratios (see Methods) were significantly different for
TgMyoA from untreated and tachypleginA-treated parasites (0.7760.07% [best fit 6 standard error; 95% confidence interval 6.3–9.1%] and
0.2760.02% [95% confidence interval 2.3–3.1%], respectively).
doi:10.1371/journal.ppat.1000720.g005
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It is not understood why only half of the TgMLC1 becomes
modified after compound treatment. The ratio of
TgMyoA:TgMLC1:TgGAP45:TgGAP50 in the myosin motor
complex is thought to be 1:1:1:1 [14]. However, if individual motor
complexes were to stably associate with one another, the factor
responsible for the modification might have access to some but not all
of the TgMLC1 molecules. When Myc-tagged TgMLC1 was
expressed in parasites (which also express untagged, endogenous
TgMLC1), affinity purification of myosin motor complexes by anti-
Myc immunoprecipitation brought down Myc-tagged, but not
untagged TgMLC1 (data not shown), suggesting that individual
motor complexes do not physically associate with each other.
Alternatively, the compound might be compartmentalized within the
parasite or the efficiency with which TgMLC1 becomes modified
could be influenced by other posttranslational modifications. The
phosphorylated form of TgMLC1 does not shift downward in
response to tachypleginA (e.g., Figs. 1C & S2), suggesting that the
unphosphorylated form of TgMLC1 is indeed preferentially
modified. Further work will be required to identify all the
posttranslational modifications present on TgMLC1 and to deter-
mine whether some combination of pre-existing modifications is
responsible for the observation that the stoichiometry of modification
never reaches 100%. It is intriguing to note that when amino acids 1–
79 of TgMLC1 were fused to YFP, the electrophoretic mobility shift
occurred to near completion in the presence of compound (Fig. 3B).
This could indicate that the C-terminus of the protein serves an
autoinhibitory function, blocking the modification; the extent of the
autoinhibition could depend on other posttranslational modifications.
Regardless of the reason for the substoichiometric modification of
TgMLC1, given that the myosin motor complexes isolated from
tachypleginA-treated parasites and analyzed in the in vitro motility
assays contained a roughly 1:1 ratio of modified:unmodified
TgMLC1, it is likely that the modification has an even more
profound effect on TgMyoA function than described here. Indeed,
the decrease in calculated duty ratio for the ensemble of myosin
motor complexes after tachypleginA treatment could reflect the
mechanical capacity of a heterogeneous population of motor
complexes, half of which behave like wild-type complexes while the
other half (with a modified TgMLC1) do not contribute
substantially to actin filament movement. This simple scenario
could account for the apparent reduction in duty ratio by effectively
reducing the number of active motors on the motility surface.
TachypleginA does not alter the electrophoretic mobility of
TgMLC1 when added to cell extracts or isolated myosin motor
complexes, nor does it affect TgMyoA activity when added directly to
the in vitromotility assay. It is possible that tachypleginA or a metabolic
product of tachypleginA binds directly to TgMLC1 in intact parasites
to cause the electrophoretic mobility shift, and that some parasite factor
required for this to occur is disrupted or lost during parasite extraction.
Alternatively, TgMLC1may not be the direct target of the compound,
but rather becomes modified in intact parasites as a downstream
consequence of tachypleginA interacting with some other target(s)
within the parasite. In support of this hypothesis, we have shown that
tachypleginA also inhibits microneme secretion [26]. Since microneme
secretion does not require a functional myosin motor complex [8]), this
observation suggests that tachypleginA perturbs more than one
signaling pathway within the parasite. Disruption of these other
pathways may contribute to the inhibition of invasion and motility in
the presence of tachypleginA. Attempts to identify the direct target of
tachypleginA are currently underway, and are likely to provide new
insights into the signaling pathways that control parasite motility and
microneme secretion.
Studies of myosin motor complex function and regulation are
important for two reasons. From a biophysical viewpoint, many
questions remain about how the Class XIV myosins, which have a
number of unusual features compared to other myosins [9,10],
generate the force required to propel the parasites during gliding
motility and invasion. Secondly, because Class XIV myosins are
found in apicomplexans and their close phylogenetic relatives, but
not in humans (see [38] for review), and are essential for parasite
survival [8], they represent potential new drug targets. We have
shown here that the machinery that regulates TgMyoA function is
susceptible to pharmacological perturbation (see also [39]). A
better understanding of how Class XIV myosins function and how
they are regulated by their associated light chains may lead to new
chemotherapeutic approaches to the treatment of disease caused
by T. gondii and other apicomplexan parasites.
Materials and Methods
Cell culture
Parasites were maintained by continuous passage in human
foreskin fibroblasts (HFFs) in Dulbecco’s Modified Eagle’s Media
(DMEM) containing 1% (v/v) heat inactivated fetal bovine serum
(FBS), 1% (v/v) penicillin/streptomycin mix (Invitrogen, Carlsbad
CA) and 1% (v/v) 10 mM HEPES pH 7.0 (Invitrogen) as
previously described [40].
Compound storage and use
All small-molecule inhibitors were either purchased from
ChemBridge Corporation (San Diego CA) or synthesized as
described and stored at 220uC. Compound stock solutions were
dissolved to a concentration of 40 mM in high quality DMSO and
stored in the dark at 220uC. Unless otherwise noted, compounds
were diluted to a concentration of 100 mM in Hanks Balanced Salt
Solution immediately before use. Invasion and motility assays were
performed as previously described [26].
Western blotting
Protein samples were boiled in 1X SDS-PAGE sample buffer in
the presence of 1.25% (v/v) b-mercaptoethanol for five minutes.
Proteins were either visualized directly by staining with silver [41],
Colloidal Coomassie Blue or SYPRO Ruby (Bio-Rad, Hercules
CA), or transferred to nitrocellulose or PVDF [42]. For western
blot analysis, membranes were blocked with 5% (w/v) dry milk in
Tris-buffered saline containing 0.1% (v/v) Tween (TBS-T) for one
hour to overnight. Blots were incubated with primary antibody for
one hour and secondary antibody conjugated to horseradish
peroxidase for 30 minutes, agitating at 25uC. Anti-TgMLC1
antibody was diluted 1:2,000. Anti-GFP (Invitrogen) and anti-Myc
monoclonal antibody 9E10 (Developmental Studies Hybridoma
Bank, Iowa City IA) were diluted 1:1,000.
2D gel electrophoresis
Protein pellets were resuspended in lysis buffer (10 mM Tris
pH 7.4 containing 0.5% (v/v) protease inhibitor mix (Sigma
Catalog # P8340, St. Louis MO) and 50 mg/ml RNase/DNase),
followed by four freeze/thaw cycles in liquid nitrogen. SDS buffer
(0.3% (w/v) SDS and 200 mM DTT) was added to samples,
which were then sonicated in a water bath sonicator (Branson,
Danbury CT) for 20 minutes at 25uC, incubated at 55uC for 10
minutes and incubated at 25uC for two hours. Octyl buffer (9.9M
urea, 4% (w/v) octyl-b-D-glucopyranoside, 100 mM DTT) was
added to samples and incubated at 25uC for one hour. Ampholytes
(GE Healthcare, Piscataway NJ) and bromophenol blue were
added to a final concentration of 0.5% (v/v) and 0.01% (v/v),
respectively. Insoluble proteins were pelleted at 15,0006g for 30
minutes at 25uC. Soluble proteins were infiltrated into either 11 or
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18 cm Immobiline DryStrip Gels (GE Healthcare) overnight and
proteins were resolved as per manufacturer’s instructions. The
strips were then washed for 10 minutes in equilibration buffer
(50 mM Tris pH 8, 6 M urea, 30% glycerol, 2% SDS) containing
1% DTT, followed by a second wash in equilibration buffer
containing 1.25% iodoacetamide, and resolved by SDS-PAGE.
35S-labeling and immunoprecipitation
Parasites were metabolically labeled with [35S] methionine-cysteine
(Perkin Elmer, Waltham MA) for 20 to 24 hours as previously
described [43] and extracted in IP lysis buffer (1% (v/v) TX-100,
50 mM Tris-Cl pH 8, 150 mM NaCl, 5 mM EDTA) with 1:100
protease inhibitors on ice for 10 minutes. Extracts were clarified at
13,0006g for 30 minutes at 4uC. Protein extracts were incubated with
a 1:1,000 dilution of anti-TgGAP45 [14] for 60 minutes at 4uC,
followed by an additional 60 minute incubation with protein A or G
conjugated to Sepharose (Zymed, San Francisco CA). The beads were
washed with 60 volumes of IP lysis buffer. Proteins were eluted from
the beads for 1D gel electrophoresis by boiling for five minutes in 1X
SDS-PAGE sample buffer with or without reducing agent. Proteins
were eluted for 2D gel electrophoresis (15 minutes at 25uC) in 1.2 mM
Tris-Cl pH 7.4, 0.024% (w/v) SDS, 8 M urea, 3.2% (w/v) octyl-b-D-
glucopyranoside, 80 mM DTT. Ampholytes and bromophenol blue
were added to a final concentration of 0.5% (v/v) and 0.01% (v/v),
respectively. Insoluble proteins were pelleted at 15,0006g for 30
minutes at 25uC.
Effect of tachypleginA on isolated myosin motor
complexes
35S-labeled myosin motor complexes were isolated by anti-
TgGAP45 immunoprecipitation as described above. Protein A
agarose beads with attached motor complexes were incubated in
DMSO or 100 mM tachypleginA for 20 minutes at 25uC. Proteins
were eluted from the beads with 1X SDS-PAGE sample buffer,
resolved by SDS-PAGE and visualized by autoradiography.
Cloning FLAG- and Myc-tagged TgMLC1
Total tachyzoite RNA was extracted using TRI reagent (Sigma)
according to the manufacturer’s instructions. The SuperScript
first-strand synthesis system (Invitrogen) was used to generate
oligo(dT)-primed first-strand cDNA from 5 mg RNA. The
sequence of all primers used to create TgMLC1 constructs are
listed in Table S1. Myc-tagged and FLAG-tagged TgMLC1 were
amplified from total parasite cDNA using primer sets Myc-
TgMLC1 59/TgMLC1 39 A or FLAG-TgMLC1 59/TgMLC1 39
A. TgMLC1 PCR products were cloned in the TOPO TA vector
(Invitrogen) as per manufacturer’s instructions. TgMLC1 was
subsequently subcloned from the TOPO TA vector into the T.
gondii expression vector, TUBIMC1YFP/sagCAT [44].
Cloning TgMLC1 truncation mutants
To clone Myc-TgMLC11–193 and Myc-TgMLC180–213 expres-
sion constructs, the Myc-TgMLC1 TOPO plasmid was used as a
template for PCR with primers Myc-TgMLC1 59/TgMLC1 aa
193 39 and Myc-TgMLC1 aa 80 59/TgMLC1 39 A, respectively.
PCR products were cloned in the TOPO TA vector and
subcloned using BglII and AvrII restriction sites into TUBIM-
C1YFP/sagCAT. To clone TgMLC11–79YFP, TgMLC140–79YFP
and TgMLC160–79YFP, Myc-TgMLC1 TOPO was used as a
template to amplify aa1–79, aa40–79 and aa60–79 of TgMLC1
using primers TgMLC1 59 B/TgMLC1 79 39, TgMLC1aa40 59/
TgMLC1 79 39 and TgMLC1 aa60 59/TgMLC1 79 39,
respectively. PCR products were cloned in the TOPO TA vector
and subcloned using BglII and AvrII restriction sites into
TUBIMC1YFP/sagCAT.
Immunofluoresence microscopy
Intracellular parasites were grown on confluent HFF monolayers
for approximately 24 hours. Cells were fixed with 2% (v/v)
formaldehyde diluted in PBS for 15 minutes at 25uC. Cells were
permeabilized with 0.25% (v/v) TX-100 diluted in PBS for 10
minutes at 25uC. Primary and secondary antibodies were diluted in
PBS containing 0.5% (w/v) BSA, filtered through a 0.22 mm filter
and incubated with cells for 15minutes at 25uC. Anti-IMC1 and anti-
GFP antibodies were diluted 1:1,000. Secondary antibodies conju-
gated to either Alexa 488 or 546 (Invitrogen) were diluted 1:500.
Myosin motor complex isolation for in vitro motility
assays
5286109 extracellular parasites were treated with DMSO or
100 mM tachypleginA and extracted in 3 ml FLAG lysis buffer
(10 mM imidazole pH 7, 300 mM NaCl, 1 mM EGTA, 5 mM
MgCl2, 1% (v/v) TX-100, 2 mM ATP, 2 mM DTT and 1:100
protease inhibitor cocktail) on ice for 10 minutes. Protein extracts
were clarified at 10,0006g for 30 minutes. Before use, FLAG
affinity resin (Sigma) was equilibrated in 0.1M glycine pH 3.5 and
washed with FLAG lysis buffer as per manufacturer’s instructions.
Protein extracts and approximately 400 ml FLAG affinity resin
were agitated for two hours at 4uC. Resins were extensively
washed with FLAG wash buffer (10 mM imidazole pH 7,
300 mM NaCl, 1 mM EDTA, 1 mM ATP, 1 mM DTT, 1%
(v/v) TX-100 and 1:500 protease inhibitors) to remove any
unbound proteins, and FLAG-TgMLC1 and its associated
proteins were eluted from the resin using 100 ml 0.2 mg/ml
FLAG peptide (Sigma) in FLAG wash buffer, agitating for 10
minutes. Remaining protein bound to the beads was eluted with a
second wash of 50 ml of 0.2 mg/ml FLAG peptide. Eluates were
combined and either stored on ice or diluted with 1/3 volume
100% (v/v) glycerol and stored at -20uC and used for functional
assays within 48 hours. Isolated myosin motor complexes were
resolved by SDS-PAGE along with protein standards (Phosphor-
ylase b 94kDa; Albumin 67kDa; Ovalbumin 43kDa; Carbonic
anhydrase 30kDa; Trypsin inhibitor 20.1kDa and a-lactalbumin
14.4kDa (Pharmacia LKB, Piscataway, NJ)) of known concentra-
tion. Gels were stained with SYPRO Ruby (Bio-Rad) as per
manufacturer’s instructions and imaged using a Bio-Rad FX-
imager. The fluorescence intensity of the protein standards was
compared to the fluorescence intensity of TgMyoA to determine
the amount of myosin isolated from both DMSO- and
tachypleginA-treated parasites.
TgMyoA in vitro motility assays
Isolated myosin motor complexes were added to flow cells [33]
and incubated for two minutes to allow protein to adhere to
nitrocellulose-coated coverslips, followed by the addition of
0.5 mg/ml BSA in Actin Buffer (25 mM KCl, 25 mM imidazole,
1 mM EGTA, 4 mM MgCl2, 10 mM DTT, pH 7.4) to block any
unoccupied sites. The flow cells were then washed with Actin
Buffer three times, twice infused with TRITC-phalloidin labeled
chicken skeletal muscle actin filaments [33] in Actin Buffer
containing an oxygen scavenger system (0.1 mg/ml glucose
oxidase, 0.018 mg/ml catalase, 2.3 mg/ml glucose), and incubat-
ed for 30 seconds. Finally, flow cells were washed with Actin Buffer
containing 0.5% (v/v) methylcellulose and 1 mM ATP. Myosin
activity was monitored by video microscopy and actin filament
velocities were determined as previously described [31,33]. For
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each myosin concentration at least 19 filaments (mean 42, range
19–82) from five different areas of the coverslip were tracked at
one frame per second until the filament exited the field or stopped
moving for two or more frames. Stationary filaments as well as
those that were undergoing reptation (i.e., exhibiting random
motion parallel to the filament’s long axis) were excluded from the
analysis.
To determine the TgMyoA duty ratio, the amount of myosin
capable of interacting with a given length of actin filament was
determined based on the concentration of TgMyoA added to the
coverslip and surface area of the coverslip as previously described
[33]. Actin filament lengths were measured as previously described
[31], thus allowing the number of myosin heads capable of
interacting with any given actin filament to be estimated. Duty
ratios were determined by fitting data to the equation V=
(a6Vmax)6[12(12f)
n] where V is the measured actin filament
velocity, f is duty ratio, n is the number of myosin heads capable of
interacting with the actin filament, and a is an ‘‘efficiency factor,’’
which is a parameter of the fit [33,45]. Data from a total of 195
(control) and 235 (tachypleginA) filaments were used to generate
the fits shown in Fig. 5C. The absolute duty ratios obtained from
the fits assume that all heads on the motility surface are functional.
This may not be the case if the number of functional heads is less
such that the duty ratios are underestimates. Since there is no a
priori reason to assume that the DMSO- and tachypleginA-treated
preparations would bind differentially to the motility surface, any
differences in the duty ratios between the control and compound-
treated samples are assumed to reflect true relative differences.
Data were analyzed using GraphPad Prism v.5.01 software.
Isolation of TgMLC1 for mass spectrometry analysis
For SILAC experiments cells were grown essentially as
described [28]. Briefly, infected HFF cells were cultured at 37uC
and 5% CO2 for four days in DMEM deficient in L-arginine and
L-lysine (prepared by Cambridge Isotope Laboratories, Inc.
Andover, MA) supplemented with 10% dialyzed fetal bovine
serum (HyClone, Logan, UT); 50 units/ml penicillin and 50 mg/
ml streptomycin (Invitrogen, Carlsbad, CA); and either 146 mg/l
unlabeled L-lysine and 84 mg/l unlabeled L-arginine (‘‘light’’), or
146 mg/l 13C6-,
15N2-L-lysine and 84 mg/l
13C6-,
15N4-L-
arginine (‘‘heavy’’, Cambridge Isotope Laboratories, Inc., And-
over, MA). Both heavy and light media were also supplemented
with 30–40 mg/l of unlabeled L-proline. Heavy parasites were
treated with tachypleginA and light parasites were treated with
DMSO for 20 minutes at 25uC. Parasites were extracted in FLAG
lysis buffer and myosin motor complexes were purified using
FLAG affinity resin as described above. Heavy and light motor
complexes were combined and precipitated with 10 volumes of
acetone at 220uC overnight. Proteins were pelleted at 10,0006g
for 30 minutes at 4uC, incubated in 90% acetone at 220uC for 30
minutes and pelleted as before. Pellets were allowed to dry at 25uC
and then solubilized for 2D gel electrophoresis as described above.
Gels were stained with Colloidal Coomassie Blue and spots were
excised and subjected to in-gel tryptic digestion as described
previously [46]. Mass measurements were made in an LTQ-
Orbitrap hybrid mass spectrometer (Thermo Fisher Scientific, San
Jose, CA) which was set up with a liquid chromatography interface
essentially as described [47]. Analysis of samples employed a
precursor MS1 scan in the Orbitrap at 30,000 resolution, followed
by 10 MS/MS scans in the LTQ linear ion trap on the most
abundant ions identified in the precursor scan. Dynamic exclusion
was set at 30 seconds with a repeat count of 3. Initial Sequest
analysis of tandem mass spectra was conducted using the
TgMLC1 amino acid sequence, requiring no enzyme specificity,
allowing a 30ppm window around the precursor mass, and
allowing differential mass additions of 15.99491 for methionine,
10.00827 for arginine and 8.01420 for lysine. A static increase of
57.02146 was set on cysteines for carbamidomethylation. Quan-
tification of SILAC data was done manually as described [48]. For
the non-SILAC sample analysis Sequest searches of tandem mass
spectra obtained in the LTQ linear ion trap were conducted with a
2Da mass tolerance of the precursor and differential modification
of cysteine from 1–353 (i.e., 353 searches were performed, with the
differential modification of cysteine increasing incrementally by
one Da each search). Differential searches were also performed for
potential phosphorylation, acetylation and mono-, di-, and tri-
methylation of peptide V46GEYDGACESPSCR59.
Supporting Information
Figure S1 Identification of two analogs of tachypleginA that
induce the TgMLC1 electrophoretic mobility shift. Structures of
tachypleginA, A-2 and A-3 (left) and demonstration by anti-
TgMLC1 western blot (right) that all three compounds induce a
similar electrophoretic mobility shift of TgMLC1 at 100 mM.
Unmodified and modified forms of TgMLC1 are indicated by blue
and red arrowheads, respectively. All three compounds inhibit
parasite motility and invasion at 100 mM (data not shown).
Found at: doi:10.1371/journal.ppat.1000720.s001 (0.13 MB TIF)
Figure S2 Myc-tagged TgMLC1 undergoes the electrophoretic
mobility shift in response to tachypleginA treatment. Myc-
TgMLC1-WT expressing parasites were treated with 100 mM
tachypleginA or an equivalent amount of DMSO, extracted,
resolved by 2D gel electrophoresis and analyzed by western blot.
Myc-TgMLC1-WT (green brackets) and endogenous TgMLC1
(blue brackets) are both modified by tachypleginA.
Found at: doi:10.1371/journal.ppat.1000720.s002 (0.33 MB TIF)
Figure S3 Localization of TgMLC1 truncation mutants. Dual
immunofluorescence labeling of parasites expressing Myc-
TgMLC1-WT, Myc-TgMLC180–213 and Myc-TgMLC11–193 with
antibodies against TgGAP45 (red) and the Myc epitope tag
(green). Myc-TgMLC1-WT and Myc-TgMLC11–193 localize to
the parasite periphery, whereas Myc-TgMLC180–213 localizes to
the cytosol.
Found at: doi:10.1371/journal.ppat.1000720.s003 (0.51 MB TIF)
Figure S4 MS/MS spectrum of the peptide V46GEYDGA-
CESPSCR59. Low energy collision-induced dissociation MS/MS
spectrum for the doubly-charged ion of the V46GEYDGA-
CESPSCR59 peptide. This spectrum was observed multiple times
in both heavy and light forms during the same chromatographic
time that quantitative mass spectrometry (SILAC) measurements
were taken on the precursor ions (see Fig. 4). C# indicates a
carbamidomethyl cysteine residue generated by alkylation with
iodoacetamide prior to running the 2D gels.
Found at: doi:10.1371/journal.ppat.1000720.s004 (0.75 MB TIF)
Figure S5 Estimation of the relative abundance of peptide
V46GEYDGACESPSCR59 in the two forms of TgMLC1. Using
Xcalibur software (Thermo Scientific), the relative abundance of
V46GEYDGACESPSCR59 in the upper and lower forms of
TgMLC1 was semi-quantitatively compared to the relative
abundance of a dominant background ion, [(Si(CH3)2O)6 + H+]+
(monoisotopic mass = 445.12). The relative abundance of
V46GEYDGACESPSCR59 to the background ion in the upper
spot was approximately 225 times greater than that in the lower
spot (i.e., the monoisotopic peak of the light V46GEYDGA-
CESPSCR59 peptide in the lower spot had to be raised 225 times
in value to achieve the same signal observed in the upper spot).
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C# indicates a carbamidomethyl cysteine residue generated by
alkylation with iodoacetamide prior to running the 2D gels.
Found at: doi:10.1371/journal.ppat.1000720.s005 (0.39 MB TIF)
Figure S6 Determination of the TgMyoA concentration in
purified motor complex preparations. The concentration of
TgMyoA recovered from FLAG-TgMLC1 expressing parasites
treated with either DMSO or 100 mM tachypleginA was
determined by staining the SDS-PAGE-resolved preparations
with SYPRO Ruby and comparing the fluorescence intensity of
the TgMyoA band with known amounts of four protein standards
(see Materials and Methods). Numbers on the left indicate
molecular mass in kDa and numbers above lanes 1–7 indicate
the amount of each standard (in mg) loaded in that lane.
Found at: doi:10.1371/journal.ppat.1000720.s006 (0.40 MB TIF)
Text S1 Supplemental methods and references
Found at: doi:10.1371/journal.ppat.1000720.s007 (0.30 MB PDF)
Table S1 TgMLC1 primer sequences.
Found at: doi:10.1371/journal.ppat.1000720.s008 (0.05 MB PDF)
Video S1 In vitro motility of purified TgMyoA motor complexes
from tachypleginA-treated parasites. FLAG-TgMLC1-expressing
parasites were treated for 15 minutes at 24uC with 100 mM
tachypleginA (final DMSO concentration, 0.25% (vol:vol)).
Myosin motor complexes were isolated from the treated parasites
by anti-FLAG affinity chromatography and adsorbed to nitrocel-
lulose-coated coverslips at a TgMyoA concentration of 8.6 mg/ml.
TRITC-phalloidin-labeled actin filaments were added to the
immobilized motor complexes, and actin filament displacement
was captured by videomicroscopy as described in Materials and
Methods. Filament displacement is shown in real time; scale
bars = 5 mm.
Found at: doi:10.1371/journal.ppat.1000720.s009 (7.8 MB ZIP)
Video S2 In vitro motility of purified TgMyoA motor complexes
from control parasites. FLAG-TgMLC1-expressing parasites were
treated for 15 minutes at 24uC with an amount of DMSO
equivalent to that used in Video S1 (0.25% (vol:vol)). Myosin
motor complexes were isolated from the treated parasites by anti-
FLAG affinity chromatography and adsorbed to nitrocellulose-
coated coverslips at a TgMyoA concentration of 7.4 mg/ml.
TRITC-phalloidin-labeled actin filaments were added to the
immobilized motor complexes, and actin filament displacement
was captured by videomicroscopy as described in Materials and
Methods. Filament displacement is shown in real time; scale
bars = 5 mm.
Found at: doi:10.1371/journal.ppat.1000720.s010 (7.7 MB ZIP)
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